{"id":"https://openalex.org/W2149118348","doi":"https://doi.org/10.1002/art.22379","title":"Adalimumab for long\u2010term treatment of psoriatic arthritis: Forty\u2010eight week data from the adalimumab effectiveness in psoriatic arthritis trial","display_name":"Adalimumab for long\u2010term treatment of psoriatic arthritis: Forty\u2010eight week data from the adalimumab effectiveness in psoriatic arthritis trial","publication_year":2007,"publication_date":"2007-01-30","ids":{"openalex":"https://openalex.org/W2149118348","doi":"https://doi.org/10.1002/art.22379","mag":"2149118348","pmid":"https://pubmed.ncbi.nlm.nih.gov/17265483"},"language":"en","primary_location":{"id":"doi:10.1002/art.22379","doi":"https://doi.org/10.1002/art.22379","is_oa":false,"landing_page_url":"https://doi.org/10.1002/art.22379","pdf_url":null,"source":{"id":"https://openalex.org/S132787887","display_name":"Arthritis & Rheumatism","issn_l":"0004-3591","issn":["0004-3591","1529-0131"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatism","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049489990","display_name":"Dafna D. Gladman","orcid":"https://orcid.org/0000-0002-9074-0592","observed_orcids":["https://orcid.org/0000-0002-9074-0592"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I2799337515","display_name":"Toronto Western Hospital","ror":"https://ror.org/03qv8yq19","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2799337515"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Dafna D. Gladman","raw_affiliation_strings":["University of Toronto, and Toronto Western Hospital, Toronto, Ontario, Canada. dafna.gladman@utoronto.ca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Toronto, and Toronto Western Hospital, Toronto, Ontario, Canada. dafna.gladman@utoronto.ca","institution_ids":["https://openalex.org/I185261750","https://openalex.org/I2799337515"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081778211","display_name":"Philip J. Mease","orcid":"https://orcid.org/0000-0002-6620-0457","observed_orcids":["https://orcid.org/0000-0002-6620-0457"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip J. Mease","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020367519","display_name":"Christopher T. Ritchlin","orcid":"https://orcid.org/0000-0002-2602-1219","observed_orcids":["https://orcid.org/0000-0002-2602-1219"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher T. Ritchlin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079748913","display_name":"Ernest Choy","orcid":"https://orcid.org/0000-0003-4459-8609","observed_orcids":["https://orcid.org/0000-0003-4459-8609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ernest H. S. Choy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038322725","display_name":"John Turner Sharp","orcid":"https://orcid.org/0000-0002-7429-9047","observed_orcids":["https://orcid.org/0000-0002-7429-9047"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John T. Sharp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045706732","display_name":"Peter A. Ory","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter A. Ory","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047314880","display_name":"Renee J. Perdok","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Renee J. Perdok","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5040915422","display_name":"Eric H. Sasso","orcid":"https://orcid.org/0000-0001-6891-7980","observed_orcids":["https://orcid.org/0000-0001-6891-7980"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric H. Sasso","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":16.965,"has_fulltext":false,"cited_by_count":288,"citation_normalized_percentile":{"value":0.99575119,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"56","issue":"2","first_page":"476","last_page":"488"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":1.0},{"id":"https://openalex.org/keywords/anti-tnf-therapy","display_name":"anti-TNF therapy","score":0.8519999980926514},{"id":"https://openalex.org/keywords/long-term-treatment","display_name":"long-term treatment","score":0.7289999723434448},{"id":"https://openalex.org/keywords/radiographic-progression","display_name":"radiographic progression","score":0.7429999709129333},{"id":"https://openalex.org/keywords/joint-damage","display_name":"joint destruction","score":0.4860000014305115},{"id":"https://openalex.org/keywords/acr-response-rates","display_name":"ACR response rates","score":0.609000027179718},{"id":"https://openalex.org/keywords/pasi-response","display_name":"PASI response","score":0.828000009059906},{"id":"https://openalex.org/keywords/disability","display_name":"disability","score":0.4180000126361847},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.9490000009536743},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6819999814033508},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6200000047683716},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.48500001430511475},{"id":"https://openalex.org/keywords/rheumatoid-factor","display_name":"rheumatoid factor","score":0.4909999966621399},{"id":"https://openalex.org/keywords/hla-dr1","display_name":"HLA-DR1","score":0.4790000021457672},{"id":"https://openalex.org/keywords/hla-dr4","display_name":"HLA-DR4","score":0.46700000762939453},{"id":"https://openalex.org/keywords/hla-dr5","display_name":"HLA-DR5","score":0.5289999842643738}],"concepts":[{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.9778213500976562},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9464762210845947},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.8120169043540955},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6519054174423218},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6276617050170898},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.554054856300354},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.525780439376831},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5027656555175781},{"id":"https://openalex.org/C198451711","wikidata":"https://www.wikidata.org/wiki/Q327657","display_name":"Rheumatology","level":2,"score":0.48270654678344727},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.42095544934272766},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.3812996745109558},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.2915336489677429},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06147220730781555},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001175","descriptor_name":"Arthrography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004185","descriptor_name":"Disability Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015535","descriptor_name":"Arthritis, Psoriatic","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D015535","descriptor_name":"Arthritis, Psoriatic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/art.22379","doi":"https://doi.org/10.1002/art.22379","is_oa":false,"landing_page_url":"https://doi.org/10.1002/art.22379","pdf_url":null,"source":{"id":"https://openalex.org/S132787887","display_name":"Arthritis & Rheumatism","issn_l":"0004-3591","issn":["0004-3591","1529-0131"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatism","raw_type":"journal-article"},{"id":"pmid:17265483","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17265483","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis and rheumatism","raw_type":"Journal Article"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/76e5d5fd-bedd-45ee-8a70-43a42ab28e43","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/76e5d5fd-bedd-45ee-8a70-43a42ab28e43","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Gladman, D D, Mease, P J, Ritchlin, C T, Choy, E H S, Sharp, J T, Ory, P A, Perdok, R J & Sasso, E H 2007, 'Adalimumab for long-term treatment of psoriatic arthritis - Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial', Arthritis & Rheumatism, vol. 56, no. 2, pp. 476 - 488. https://doi.org/10.1002/art.22379","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W45832520","https://openalex.org/W137314200","https://openalex.org/W143191285","https://openalex.org/W165899179","https://openalex.org/W1768811307","https://openalex.org/W1968958817","https://openalex.org/W1979364075","https://openalex.org/W1996389186","https://openalex.org/W1996437423","https://openalex.org/W2003860570","https://openalex.org/W2016713237","https://openalex.org/W2018583759","https://openalex.org/W2046628605","https://openalex.org/W2050168849","https://openalex.org/W2056516039","https://openalex.org/W2067327580","https://openalex.org/W2094124191","https://openalex.org/W2096965824","https://openalex.org/W2098689226","https://openalex.org/W2116843833","https://openalex.org/W2119275077","https://openalex.org/W2122980756","https://openalex.org/W2124162112","https://openalex.org/W2124279530","https://openalex.org/W2128840310","https://openalex.org/W2130454548","https://openalex.org/W2133541603","https://openalex.org/W2133696182","https://openalex.org/W2137833678","https://openalex.org/W2139788459","https://openalex.org/W2145778588","https://openalex.org/W2149168537","https://openalex.org/W2151546682","https://openalex.org/W2156796142","https://openalex.org/W2158620918","https://openalex.org/W2159106700","https://openalex.org/W2167404036","https://openalex.org/W2168698481","https://openalex.org/W2400559720","https://openalex.org/W2410144852","https://openalex.org/W2413223450","https://openalex.org/W2414425175","https://openalex.org/W4232214719","https://openalex.org/W6683694474"],"related_works":["https://openalex.org/W7100573399","https://openalex.org/W2133696182","https://openalex.org/W2159697181","https://openalex.org/W2094642199","https://openalex.org/W7097001205","https://openalex.org/W1922566561","https://openalex.org/W2145093133","https://openalex.org/W2112675962","https://openalex.org/W2610729538","https://openalex.org/W2097007448"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,36,107,139,195,199,222,228],"efficacy":[4,85,276],"and":[5,75,83,90,125,132,142,152,165,176,180,219,235,249,251,274,291,301,306],"safety":[6,338],"of":[7,48,110,119,129,198,278],"treatment":[8],"with":[9,25,78,138,315],"adalimumab,":[10,59],"a":[11,44,336],"fully":[12],"human":[13],"anti-tumor":[14],"necrosis":[15],"factor":[16],"(anti-TNF)":[17],"monoclonal":[18],"antibody,":[19],"over":[20,98,310],"48":[21,74,99,244,311],"weeks":[22,245,261,267,312],"in":[23,39,52,91,168,190,205,227,313,320],"patients":[24,105,239,255,280,314],"moderate":[26],"to":[27,56,213],"severe":[28],"psoriatic":[29],"arthritis":[30],"(PsA).":[31],"METHODS:":[32],"Patients":[33],"who":[34,240,256,317],"completed":[35],"Adalimumab":[37,271,287,298,334],"Effectiveness":[38],"Psoriatic":[40],"Arthritis":[41],"Trial":[42],"(ADEPT),":[43],"24-week,":[45],"double-blind":[46],"study":[47],"adalimumab":[49,108,242,264],"versus":[50],"placebo":[51,258],"PsA,":[53],"could":[54],"elect":[55],"receive":[57],"open-label":[58],"40":[60],"mg":[61],"subcutaneously":[62],"every":[63],"other":[64],"week":[65,67,73,103,211,214,217,220,295,341],"after":[66],"24.":[68],"Radiographs":[69],"were":[70,76,87,96,172,184,208,233,281,318],"obtained":[71,80],"at":[72,285,324],"read":[77],"radiographs":[79],"previously.":[81],"Clinical":[82],"radiographic":[84,275,308,332],"data":[86,95],"analyzed":[88,185],"overall":[89],"patient":[92],"subsets.":[93],"Safety":[94],"collected":[97],"weeks.":[100],"RESULTS:":[101],"At":[102,216],"48,":[104,221],"from":[106,210,225],"arm":[109],"ADEPT":[111],"(n":[112,146,246,268],"=":[113,147,247,269],"151)":[114],"had":[115,335],"achieved":[116],"American":[117],"College":[118],"Rheumatology":[120],"20%":[121],"improvement":[122],"(ACR20),":[123],"ACR50,":[124],"ACR70":[126],"response":[127,154,182],"rates":[128,155,183],"56%,":[130],"44%,":[131],"30%,":[133],"respectively.":[134],"Among":[135],"those":[136],"evaluated":[137],"Psoriasis":[140],"Area":[141],"Severity":[143],"Index":[144,197],"(PASI)":[145],"69),":[148],"PASI50,":[149],"PASI75,":[150],"PASI90,":[151],"PASI100":[153],"(>":[156],"or":[157,160,163,331],"=50%,":[158],">":[159,162],"=75%,":[161],"=90%,":[164],"100%":[166],"reduction":[167],"PASI":[169,181],"scores,":[170],"respectively)":[171],"67%,":[173],"58%,":[174],"46%,":[175],"33%,":[177],"respectively":[178],"(ACR":[179],"using":[186],"nonresponder":[187],"imputation).":[188],"Improvements":[189],"disability,":[191,305],"as":[192],"measured":[193],"by":[194,263],"Disability":[196],"Health":[200],"Assessment":[201],"Questionnaire":[202],"(mean":[203],"change":[204],"score":[206,232],"-0.4)":[207],"sustained":[209],"24":[212,218,260,266],"48.":[215,296,342],"mean":[223],"changes":[224],"baseline":[226,325],"modified":[229],"total":[230],"Sharp":[231],"-0.1":[234],"0.1,":[236],"respectively,":[237,253],"for":[238,243,254,259,265,329],"received":[241,257],"133),":[248],"0.9":[250],"1.0,":[252],"followed":[262],"141).":[270],"demonstrated":[272],"clinical":[273,330],"regardless":[277],"whether":[279],"receiving":[282],"methotrexate":[283],"(MTX)":[284],"baseline.":[286],"was":[288,326],"generally":[289],"safe":[290],"well":[292],"tolerated":[293],"through":[294,340],"CONCLUSION:":[297],"improved":[299],"joint":[300],"skin":[302],"manifestations,":[303],"reduced":[304],"inhibited":[307],"progression":[309],"PsA":[316],"participants":[319],"ADEPT.":[321],"MTX":[322],"use":[323],"not":[327],"required":[328],"efficacy.":[333],"good":[337],"profile":[339]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":17},{"year":2015,"cited_by_count":27},{"year":2014,"cited_by_count":21},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":27}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}